聚乙二醇化重组人粒细胞集落刺激因子的临床应用进展  

Progress in Clinical Application of Pegylated Recombinant Human Graulocyte-Colony Stimulating Factor

作　　者：周建红[1] 罗文苹[1] 张日光[1] 黄慧娴[1] 刘春琳[1] ZHOU Jianhong;LUO Wenping;ZHANG Riguang;HUANG Huixian;LIU Chunlin(Department of Oncology,the Fourth Affiliated Hospital of Guangxi Medical University,Liuzhou 545005,China)

机构地区：[1]广西医科大学第四附属医院肿瘤科,广西柳州545005

出　　处：《医学综述》2021年第15期3067-3072,共6页Medical Recapitulate

基　　金：北京市希思科-齐鲁肿瘤研究基金(Y-Q201801-047)。

摘　　要：骨髓抑制是化疗常见的不良反应之一,常表现为白细胞计数及中性粒细胞减少。重组人粒细胞集落刺激因子(rhG-CSF)能够有效预防和治疗化疗后出现的发热性中性粒细胞减少症,但rhG-CSF以肾脏代谢为主,药物半衰期短,需每日皮下注射。而聚乙二醇与rhG-CSF结合形成的聚乙二醇化rhG-CSF(PEG-rhG-CSF)可改善药物的清除方法,降低清除率。与rhG-CSF相比,PEG-rhG-CSF具有注射次数少、注射剂量小、患者依从性高等优点,可显著减少化疗患者注射次数和门诊就诊次数,降低患者感染的发生率,具有更加广阔的应用前景。Myelosuppression is one of the common adverse reactions of chemotherapy,which is often manifested as leucopenia and neutropenia.Recombinant human granulocyte-colony stimulating factor(rhG-CSF)can effectively prevent and treat febrile neutropenia after chemotherapy.However,rhG-CSF is mainly metabolized in the kidney and needs daily subcutaneous injection due to its short half-life.Pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF)can improve the drug clearance method and reduce the clearance rate.Compared with rhG-CSF,PEG-rhG-CSF has the advantages of less injection times,small injection dose and high patient compliance,which can significantly reduce the injection times and outpatient visits of the patients,reduce the incidence of infection,and has a broader application prospect.

关 键 词：发热性中性粒细胞减少症 聚乙二醇化重组人粒细胞集落刺激因子 化疗 

分 类 号：R453.9[医药卫生—治疗学]